Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957318 | 0.78 | ALDH1A1 (0.45) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8327715 | 0.77 | KIF11 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL19652451 | 0.77 | LMNA (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2435306 | 0.77 | ALDH1A1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4742924 | 0.77 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL15355750 | 0.76 | CNR2 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL13537066 | 0.75 | MAPK1 (0.49) | CA1CA2CA7CA9CA12 | |
| SCHEMBL19318211 | 0.74 | ACHE (0.52) | CA1CA2ALDH1A1ALOX15MAPK1 | |
| SCHEMBL11569782 | 0.74 | KIF11 (0.64) | KIF11KCNH2SMN1; SMN2 | |
| SCHEMBL25620281 | 0.74 | LTA4H (0.52) | ALDH1A1TDP1KIF11KCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394356-B2 | Diagnostic imaging contrast agents with extended blood retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8017105-B2 | Diagnostic imaging contrast agents with extended blood retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7229606-B2 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070020185-A1 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. A DELAWARE CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070020184-A1 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. A DELAWARE CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070003479-A1 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC., A DELAWARE CORPORATION | 2007-01-04 | — | — | US | disclosed |
| EP-1716871-A2 | Diagnostic imaging contrast agents with extended blood retention | EPIX Pharmaceuticals, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-0806968-B1 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | EPIX PHARM INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-7011815-B2 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040208827-A1 | MEDICAL DIAGNOSIS; examining vasculature of a tissue, obtains a NMR image; reducing renal and hepatocellular uptake, lost less from the bloodstream, use a lower doses, retained by the blood for a prolonged period of time | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20030180223-A1 | Magnetic resonance imaging | LANTHEUS MEDICAL IMAGING, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003029257-A1 | (ETHYLENE)-(PROPENE/BUTENE)-PHOSPHODIESTER TRIAMINE PENTAACETIC ACID DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | WO | disclosed |
| EP-0806968-A2 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | Epix Medical, Inc. (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023526-A2 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | EPIX MEDICAL, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003479-A1 | Diagnostic imaging contrast agents with extended blood retention | FABP1, B2M, BHMT | CA1 3515/4885CA2 3525/4885CA7 2267/4885 |
| US-20030180223-A1 | Magnetic resonance imaging | BHMT, FABP1, FABP7 | CA1 3456/4885CA2 3512/4885CA7 2874/4885 |
| US-20040208827-A1 | MEDICAL DIAGNOSIS; examining vasculature of a tissue, obtains a NMR image; reducing renal and hepatocellular uptake, lost less from the bloodstream, use a lower doses, retained by the blood for a prolonged period of time | FABP1, BHMT, FABP3 | CA1 3203/4885CA2 2228/4885CA7 1589/4885 |
| US-20070020185-A1 | Diagnostic imaging contrast agents with extended blood retention | FABP1, B2M, BHMT | CA1 3515/4885CA2 3525/4885CA7 2267/4885 |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | FABP1, B2M, BHMT | CA1 3515/4885CA2 3525/4885CA7 2267/4885 |
| US-20070020184-A1 | Diagnostic imaging contrast agents with extended blood retention | FABP1, B2M, BHMT | CA1 3515/4885CA2 3525/4885CA7 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.